Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 4, 2011, Pages 447-455

  Yeomans, Neville D ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

acetyl salicylic acid; aspirin; cardiovascular diseases; esomeprazole; gastrointestinal hemorrhage; peptic ulcer; proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS ESOMEPRAZOLE; CLOPIDOGREL; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO;

AREA UNDER THE CURVE; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; HEART PROTECTION; HUMAN; REVIEW; RISK REDUCTION;

ANTI-ULCER AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG THERAPY, COMBINATION; HUMANS; OMEPRAZOLE; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 79960793562     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.42     Document Type: Review

References (54)

1. Trinder P, Rajaratnam G, Lewis M, Croft P. Prophylactic aspirin use in the adult general population. J. Public Health Med. 25(4), 377-380 (2003). (Pubitemid 38173612)
2. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860 (2009).
3. Antithrombotic trialists' collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324(7329), 71-86 (2002).
4. Hart J, Hawkey CJ, Lanas A et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 31, 143-149 (2010).
5. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117, 17-25 (1999). (Pubitemid 29297615)
6. Yeomans ND, Lanas AI, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther. 22, 795-801 (2005). (Pubitemid 41564359)
7. Yeomans ND, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol. 103, 2465-2473 (2008).
8. Scheiman JM, Devereaux PJ, Herlitz J et al. Prevention of peptic ulcer with esomeprazole in cardiovascular risk patients treated with low-dose acetylsalicylic acid at risk for ulcer development: a randomised, controlled trial (OBERON).Heart 97, 797-802 (2011).
9. No authors listed. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE).CAPRIE Steering Committee. Lancet 348, 1329-1339 (1996).
10. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001). (Pubitemid 32758501)
11. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am. J. Med. 110(Suppl. 1A), 62S-65S (2001). (Pubitemid 32144907)
12. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment. Pharmacol. Ther. 16(11), 1945-1953 (2002).
13. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346(26), 2033-2038 (2002). (Pubitemid 34680594)
14. Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin. Drug Saf. 10(1), 45-54 (2010).
15. Brodie DA, Chase BJ. Role of gastric acid in aspirin-induced gastric irritation in the rat. Gastroenterology 53, 604-610 (1967).
16. Elliott SL, Ferris RJ, Giraud AS, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin. Exper. Pharmacol. Physiol. 23, 432-434 (1996). (Pubitemid 26171549)
17. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 31, 514-517 (1990). (Pubitemid 20185950)
18. Küster LJ, Frölich JC. Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins 32(3), 415-423 (1986). (Pubitemid 17183341)
19. Sachar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin. Drug Metab. Toxicol. 5(9), 1113-1124 (2009).
20. Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin. Drug Invest. 24(1), 1-7 (2003).
21. Thiessen JJ. Aspirin: plasma concentration and effects. Thromb. Res. Suppl. 4, 105-111 (1983). (Pubitemid 13072602)
22. Abelo A, Andersson T, Antonsson M, Naudot A, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug. Metab. Dispos. 28, 966-972 (2000). (Pubitemid 30612617)
23. Niazi M, Andersson T, Nauclér E, Naesdal J. Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 49(2), 169-176 (2011).
24. Würtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96(5), 368-371 (2010).
25. Iñarrea P, Esteva F, Cornudella R, Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand. J. Gastroenterol. 35(3), 242-246 (2000). (Pubitemid 30217174)
26. Ekström P, Carling L, Wetterhus S et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy - a Nordic multicentre study. Scand. J. Gastroenterol. 31, 753-758 (1996). (Pubitemid 26255041)
27. Cullen D, Bardhan KD, Eisner M et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment. Pharmacol. Ther. 12, 135-140 (1998). (Pubitemid 28059980)
28. Hawkey CJ, Karrasch JA, Szczepañski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 338, 727-734 (1998). (Pubitemid 28115091)
29. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol. 101, 701-710 (2006).
30. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352(3), 238-244 (2005). (Pubitemid 40110812)
31. Lai KC, Chu KM, Hui WM et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complication. Clin. Gastroenterol. Hepatol. 4(7), 860-865 (2006).
32. Lanas A, Garcia Rodriguez LA, Arroyo MT et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 102, 507-515 (2007). (Pubitemid 46328156)
33. Okada K, Inamori M, Imajo K et al. Clinical study of upper gastrointestinal bleeding associated with low-dose aspirin in Japanese patients. Hepatogastroenterology 56(96), 1665-1669 (2009).
34. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the Prevention of Peptic Ulcers and Oesophagitis in Patients Taking Low-dose Aspirin (FAMOUS): a Phase III, randomised, double-blind, placebo-controlled trial. Lancet 374, 93-94 (2009).
35. Ng FH, Wong SY, Lam KF et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138, 82-88 (2010).
36. Laine L. GI risk and risk factors of NSAIDs. J. Cardiovasc. Pharmacol. 47(Suppl. 1), S60-S66 (2006). (Pubitemid 44651787)
37. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947-2953 (2006). (Pubitemid 46021498)
38. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch. Intern. Med. 170(9), 765-771 (2010).
39. Johnson DA. Safety of proton pump inhibitors: current evidence for osteopororis and interaction with antiplatelet agents. Curr. Gastroenterol. Rep. 12(3), 167-174 (2010).
40. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363(20), 1909-1917 (2010).
41. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterology 102, 2047-2056 (2007). (Pubitemid 47301504)
42. Giraud AS. The evolution of the gastric mucosa. In: PhD Thesis. The University of Melbourne, Melbourne, Australia (1980).
43. Dial MS. Proton pump inhibitor use and enteric infections. Am. J. Gastroenterol. 104(Suppl. 2), S10-S16 (2009).
44. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol. 103, 2890-2907 (2008).
45. Barkun AN, Bardou M, Kuipers EJ et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann. Intern. Med. 152(2), 101-113 (2010).
46. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment. Pharmacol. Ther. 29(5), 481-496 (2009).
47. Redberg RF, Benjamin EJ, Bittner V et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults. J. Am. Coll. Cardiol. 54, 1364-1405 (2009).
48. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legoretta AP. Adherence to asthma controller medication regimens. Respir. Med. 99, 1263-1267 (2005). (Pubitemid 41245312)
49. Marceau C, Lemiere C, Berbiche D, Perreault S, Blais L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J. Allergy Clin. Immunol. 118, 574-581 (2006). (Pubitemid 44301411)
50. Yentzer BA, Ade RA, Fountain JM et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 86(2), 103-108 (2010).
51. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J. Am. Coll. Cardiol. 45(3), 456-459 (2005). (Pubitemid 40186800)
52. Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med. 152(1), 1-9 (2010).
53. Sung JJ, Chan FK, Chen M et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut DOI: 10.1136/gut.2010.230292 (2011) (Epub ahead of print).
54. Din FVN, Theodoraou E, Farrington SM et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59(12), 1670-1679 (2010).